Trinean NV has announced the appointment of Philippe Stas as it’s new CEO, succeeding Dr. Marc Zabeau, who remains a member of the board of directors.
Simultaneously, Trinean has announced that the company has secured 2.7 million euro of growth financing provided by its existing investors.
“We are delighted to have Philippe on board to help drive the value of Trinean’s molecular spectroscopy solutions,” commented Dr. Gaston Matthyssens, chairman of the board and managing partner at Vesalius Biocapital.
Dr. Matthyssens continued, “We would like to thank Dr. Marc Zabeau for his outstanding contribution to the company over the past 5 years, supporting the company since it spun out from the University of Ghent, and for his continued commitment to the company as a board member.”
Prior to joining Trinean, Philippe Stas was CEO of Algonomics NV, a Belgium based biotech service provider, where he ensured the growth and subsequent trade sale of the company to Lonza Group AG (SIX Swiss Ex:LONN) in 2009.
Since then, he was the director and main driver of Lonza’s Applied Protein Services division in Cambridge (UK). Earlier, Philippe Stas held positions at Perkin Elmer and Keygene.
Philippe holds a M.Sc. in Bio-engineering (Brussels Univ.), a M.Sc. in Information Technology (Hasselt Univ.), an MBA (Univ. of Liverpool) and AMP at the Vlerick Management School.
Philippe Stas, CEO of Trinean: “It is a pleasure to join this dynamic team, delivering a unique molecular spectroscopy platform for automated and advanced analytics.”
Trinean raised 2.7 million euro to further accelerate the development of its premium analytical platform, comprising highly accurate spectrophotometry instruments, analytical software, proprietary disposables for standardized micro-volume sample analysis and highly flexible lab-automation tools.
“The continued support of Trinean’s first-in-class investors, allows us to accelerate the development of the company and to unveil its full potential”, Philippe further comments, adding “Trinean will strongly expand its sales, marketing and distribution channels”.
The first closing of this financing round was led by the Trineans’ current investors Vesalius Biocapital, Capital-E, Baekeland II Fund and Fidimec.